TRVN (Trevena Inc) Market Value to Book Value Ratio
Demand for hospital pain therapy is independent of economic cycles. The GURU.Markets service features a line chart where the market capitalization-to-balance valuation trend has reached -0.11, which represents the current value of the indicator. Trevena, Inc. (TRVN) attracts scientists with non-opioid developments and options, although it is currently optimizing expenses due to commercialization challenges regarding its flagship product.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_TRVN_-_Trevena-Inc._-_Capitalization-to-Book-Value-Ratio "TRVN Trevena Market Capitalization to Book Value Ratio (07/04/2022 - 10/19/2024) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Trevena Inc. (TRVN)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Basic company analysis:TRVN - Trevena, Inc.
The analyst is assessing the business's margin of safety during market corrections. Trevena, Inc. (TRVN) is developing innovative analgesics without opioid risks, a process that requires massive investment. The history of the market-to-book ratio reveals a gap between the share price and net assets. This coefficient identifies either an undervaluation of the business or hidden capital depreciation. The trend of this line determines the reliability of investments in R&D projects.
Direct competitors
Market Value to Book Value Ratio Biogen Inc.|NBIX (neurocrine.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Market-to-Book Ratio Biohaven Corp|Amylyx Pharmaceuticals (AMLX) - Market Cap to Net Assets Ratio|Market Cap to Book Value Multiple TRVI|Praxis Precision Medicines, Inc. (PRAX) - Market Value to Book Value Ratio|Market Value to Book Value Anavex (AVXL)|CBLL: Market Capitalization to Book Value Ratio|PRTA - Market-to-Book Ratio|ALEC - Market Cap to Net Assets Ratio|ANNX - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio OMER|NGNE (Neurogene Inc) - Market-to-Book Ratio|Market Value to Book Value Ratio AC Immune Corp (ACIU)|Capitalization to Book Value Ratio Voyager Corp|Market Capitalization to Book Value Ratio NMRA|Market Capitalization to Book Value Ratio scilexholding.com SCLX|Market Cap to Net Assets Ratio Tevogen Bio|Market Value to Book Value Alpha Cognition Inc ACOG|Market Capitalization to Book Value Ratio CGTX (Cognition Therapeutics, Inc.)|IKT: Market Capitalization to Book Value|Market Value to Book Value Ratio Cassava Sciences, Inc.|Assertio (ASRT) - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio COYA|Market Cap to Net Assets Ratio VistaGen Therapeutics Inc (VTGN)|OVID (Ovid Therapeutics Inc.) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Acumen Pharmaceuticals, Inc ABOS|Market Cap to Net Assets Ratio CervoMed Inc. (CRVO)|Alterity Therapeutics Ltd. - Market Cap to Book Value Multiple|Market Value to Book Value Ratio Clene Nanomedicine (CLNN)|PepGen Inc. (PEPG) - Market Value to Book Value|Jupiter Neurosciences (JUNS) - Market Cap to Net Assets Ratio|RLMD (Relmada Corp) - Market Value to Book Value Ratio|Market Value to Book Value Ratio Annovis Bio, Inc. (ANVS)|Capitalization to Book Value Ratio GRCE|Market Value to Book Value Ratio Firefly Neuroscience AIFF|Capitalization to Book Value Ratio anewmeds.com (KLTO)|NRSN: Market Capitalization to Book Value Ratio|RVPH - Market-to-Book Ratio|MetaVia, Inc. - Market Cap to Net Assets Ratio|NRXS: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio heliusmedical.com HSDT|PASG (Passage Bio) - Market Value to Book Value|Market Value to Book Value Ratio NEUP (Neuphoria Therapeutics, Inc.)|Market-to-Book Ratio Minerva (NERV)|Market Cap to Net Assets Ratio Athira Pharma, Inc.|Market Cap to Book Value Multiple ADXN (addextherapeutics.com)|Market Value to Book Value Ratio Alzamend Neuro|Market Value to Book Value Cyclerion Therapeutics Inc. CYCN|PTIX (Protagenic) - Market Capitalization to Book Value Ratio|Pasithea Therapeutics (KTTA) - Market-to-Book Ratio|cortigent.com (CRGT) - Market Cap to Net Assets Ratio|avenuetx.com (ATXI) - Market Value to Book Value Ratio|Market Capitalization to Book Value Ratio BCLI (BrainStorm Cell Therapeutics)|Market-to-Book Ratio CARA|Market Value to Book Value Ratio Chromocell Therapeutics Corporation CHRO|Capitalization to Book Value Ratio eliemtx.com (ELYM)|Market Capitalization to Book Value Ratio ITCI (Intra-Cellular Therapies, Inc.)|LBPH - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Marinus Pharmaceuticals, Inc. (MRNS)|NKGN - Market Value to Book Value|NeuroBo - Market Capitalization to Book Value Ratio|SAGE (Sage Therapeutics Inc) - Market Capitalization to Book Value|Market Value to Book Value Ratio Synaptogenix, Inc. (SNPX)|Capitalization to Book Value Ratio Vigil Neuro|Market Capitalization to Book Value Ratio WENA (Anew Medical, Inc.)|Market Cap to Net Assets Ratio Cerevel Therapeutics Inc CERE